Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi

Gilead Sciences, Inc. (GILD) announced that the FDA has granted accelerated approval to seladelpar for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA), in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.The candidate was approved under the brand name Livdelzi.PBC is a rare, chronic, autoimmune disease of the bile ducts that currently has no cure.PBC affects approximately 130,000 Americans, primarily ...